<DOC>
	<DOCNO>NCT03063762</DOCNO>
	<brief_summary>This open-label , multi-center , randomize , Phase 1b , adaptive , clinical study ass safety , tolerability , pharmacokinetics , pharmacodynamics , preliminary therapeutic activity RO6874281 participant unresectable advanced and/or metastatic RCC . The study consist dose-escalation part extension part .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics Therapeutic Activity RO6874281 Combination Therapy Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Unresectable advanced and/or metastatic RCC component clear cell histology and/or component sarcomatoid histology previously treat systemic therapy , include treatment adjuvant setting During dose escalation , unresectable advanced and/or metastatic RCC one prior Vascular Endothelial Growth Factor Receptor ( VEGFR ) Tyrosinekinase inhibitor ( TKI ) therapy allow At least one tumor lesion location accessible biopsy per clinical judgment treat physician Measurable disease , define RECIST v1.1 Participants unilateral pleural effusion eligible fulfill follow : ( ) New York Heart Association ( NYHA ) Class 1 ; ( b ) Global initiative obstructive lung disease ( GOLD ) test level 1 ( forced expiratory volume 1 second [ FEV1 ] / force vital capacity [ FVC ] less [ &lt; ] 0.7 FEV1 &gt; = 80 percent [ % ] predict ) Symptomatic untreated central nervous system ( CNS ) metastases Participants asymptomatic CNS metastases previous concomitant brain deficiency , define protocol Participants confirm bilateral pleural effusion Xray Episode significant cardiovascular/cerebrovascular vascular acute disease within 6 month prior Day 1 study drug administration Active uncontrolled infection Known HIV know active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Positive serology hepatitis B ( hepatitis B surface antigen [ HBsAg ] total hepatitis B core antibody [ HBcAb ] positive ) Major surgery significant traumatic injury &lt; 28 day prior first RO6874281 infusion ( exclude fine needle biopsy ) anticipation need major surgery study treatment Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 Cycle 1 Serious , nonhealing wound ; active ulcer ; untreated bone fracture Proteinuria screening , demonstrate urine protein creatinine ratio ( UPCR ) &gt; =1.0 screen History risk autoimmune disease Chronic use steroid ( include inhale )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>RO6874281</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>